Table 2 Severity and NNH estimates of procholinergic and anticholinergic AEs (reported by ≥2% of patients in the KarXT group and at >2-fold higher incidence than in the placebo group).
n/N (%) | KarXT (n = 89) | Placebo (n = 90) | NNH (95% CI) | ||||
|---|---|---|---|---|---|---|---|
Mild | Moderate | Severe | Mild | Moderate | Severe | ||
Procholinergic AEs | |||||||
Nausea | 13/15 (86.7) | 2/15 (13.3) | 0/15 (0) | 3/4 (75.0) | 1/4 (25.0) | 0/4 (0) | 9 (5, 29) |
Vomiting | 5/8 (62.5) | 3/8 (37.5) | 0/8 (0) | 3/4 (75.0) | 1/4 (25.0) | 0/4 (0) | 23 (9, −36) |
Anticholinergic AEs | |||||||
Constipation | 12/16 (75.0) | 4/16 (25.0) | 0/16 (0) | 2/3 (66.7) | 1/3 (33.3) | 0/3 (0) | 8 (5, 21) |
Dry mouth | 6/8 (75.0) | 2/8 (25.0) | 0/8 (0) | 1/1 (100) | 0/1 (0) | 0/1 (0) | 13 (8, 65) |
